Regeneus Ltd. (AU:CMB) has released an update.
Cambium Bio Limited, a Sydney-based regenerative medicine company, has updated the terms of its CEO, Karolis Rosickas, with a new engagement agreement effective from July 1, 2024. The agreement includes a fixed annual remuneration of USD$325,000 for a 4-day work week, with potential short-term incentives up to 220% of the fixed remuneration based on performance, and a retention incentive of USD$150,000 if Rosickas remains with the company until October 5, 2025.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.
